Antioxid Redox Signal 27:684712
European Journal of Clinical Nutrition , 72(1), 105111
Restores vasomotor tone: Normalizes blood pressure in models of both pharmacologically induced hypotension and hypertension 3
In terms of lipid profile improvements, GlucoVantage delivered significant results: [2] LDL cholesterol reduction: 59.8% Triglyceride reduction: 25.5% Total cholesterol reduction: 40.5% While semaglutide showed slightly better numbers in some categories (66.9% LDL reduction), dihydroberberine's natural mechanism of action and lack of severe side effects make it an extremely compelling alternative
The STEP 1 trial, for example, reported an average weight loss of 14.9% in participants receiving semaglutide, compared to just 2.4% in the placebo group
Innovent receives FDA Approval for IND application of oral GLP-1R agonist IBI3032 owenhaskins Aug 6, 2025 2 min read Innovent Biologics has announced the FDA has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial of IBI3032, the company's novel oral GLP-1R agonist
